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I.  Deletion of Ia Alloantigens is Associated with a  Loss in 
Immunogenicity of Tumor-Associated Transplantation Antigens 
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(From the Laboratory  of Immunology, National Institute of Allergy and Infectious  Diseases, 
National Institutes of Health, Bethesda,  Maryland 20014) 
The products of the major histocompatibility complex (MHC) ~ play a  major 
role in a variety of immunological reactions including allograft rejection, graft 
vs. host reactions (reviewed in reference 1), and lymphocyte-macrophage  cooper- 
ation for antibody production (2, 3) and for cellular immunity (4-6).  In addition, 
recent studies have emphasized the requirement for compatibility for at least 
part of the MHC  for effective T-cell-mediated lysis of virus-infected (7,  8) or 
trinitrophenyl-modified (9) target cells. Furthermore, Germain et al.  (10) have 
performed  experiments  which  demonstrate  that  alloantisera  direct  against 
MHC antigens can block T-cell-mediated lysis of syngeneic tumor target cells 
suggesting a close relationship between tumor-associated transplantation anti- 
gens (TATAs) and the antigens of the MHC. 
In the present study, we had the opportunity to directly analyze the relation- 
ship between immune response-associated (Ia) antigens and a TATA by compar- 
ing the antigenicity of a series of mutant lines of a strain 2 guinea pig leukemia 
of B-lymphocyte origin.  Five lines  were studied for both  the presence of an 
immunogenic TATA and Ia alloantigens. In the one leukemic line that lacked 
detectable surface Ia antigen, an immunogenic TATA was not found; however, 
cells of  this line were rejected by strain 2 guinea pigs which had been immunized 
with  cells  of any  of the  other  lines.  Thus,  the  ability  of different mutant 
leukemia  lines  to  elicit  a  tumor-specific reactivity  in  syngeneic hosts  was 
associated with the expression on the cell membrane of  the Ia alloantigens of  the 
guinea pig major histocompatibility complex (GPLA).  Moreover, a  correlation 
between membrane antigenic composition of the leukemic cells and their growth 
pattern  in  random-bred guinea pigs  was  observed,  allowing  a  more precise 
definition  of the  role  of the  serologically defined alloantigens  of the  GPLA 
complex in allograft rejection. 
Materials and Methods 
Animals.  Inbred strain  2  (St.  2),  inbred strain  13  (St.  13), random-bred  Hartley, and NIH- 
multipurpose  guinea  pigs,  300-400  g  in  weight,  were  obtained  from  the  Animal  Production 
~Abbreviations  used  in  this  paper:  CFA,  complete  Freund's  adjuvant;  EAC,  erythrocytes- 
antibody-complement  complexes;  GPLA,  guinea  pig major  histocompatibility  complex; HBSS, 
Hanks'  balanced salt solution; Ia, immune response associated;  MHC,  major histocompatibility 
complex; St. 2, strain 2; TATA, tumor-associated transplantation  antigen. 
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Section,  National Institutes  of  Health, Bethesda, Md. The guinea  pigs  were age matched, pooled, 
and randomized at the beginning  of  each experiment. 
Leukemias.  Each of  the leukemia lines  used in  this  study presumably derive  from the initial 
L2C leukemia, which arose sometime during the 1942-1953 Congdon-Lorenz study (11,  12).  The 
original  leukemia  line  had  been  carried  since  1954  by serial  cell-graft  transfer  in  inbred  St. 2  or  in 
(St.  2 x Hartley)F~  guinea pigs,  independently by Dr. E. M. Nadel and Dr. C. W. Jungeblut who 
provided starter  tumor material to  several  investigators  (13,  14).  The different  L2C lines  used in 
this  study were recently  obtained from different  laboratories,  either  from actively  transplanted 
animals  or  from  samples  preserved for  several  years in  frozen  state.  In  this  paper  the designation 
L2C will  refer  to  the  L2C leukemia  in  general,  while  the  more  specific  designations  used  below  will 
refer  to the individual  subtypes of  the leukemia. 
The L2C line  referred  as LE-L2C was  obtained in 1969  from Dr. L. S. Kaplow, Yale  University, 
New Haven, Conn., and maintained  in  our  laboratory  since  then.  The line  referred  as  BZ-L2C was 
obtained in 1974  from  Dr. B. Zbar,  NCI, Bethesda, Md.; GH-L2C was  obtained in 1974  from Dr. G. 
D. Hsiung, Veterans  Administration Hospital,  West Haven, Conn.; EN-L2C was  obtained in 1975 
from Dr. E. N. Nadel, Medical University of  South Carolina,  Charleston,  S. C.;  and LG-L2C was 
obtained in 1975  from Dr. J. W. Pearson, NCI, Bethesda, Md. After  receipt,  these  leukemias  were 
maintained by passage in St. 2 animals by the intradermal injection of 1 x  1{):' cells.  When the 
animals  appeared  moribund  and  had  leukocyte  counts  greater  than  200,000/mm  :~  they  were 
exsanguinated by cardiac puncture into a heparinized syringe. Erythrocytes were sedimented by 
addition of one-third volume of 3% gelatin in Hanks' balanced salt solution (HBSS).  The buffy 
coats containing a large number of leukemic cells were removed, the cells washed three times in 
HBSS, and preserved by slow freezing and storage at -70°C. Except when otherwise specified, all 
the experimental challenges reported here were done by injecting 10  x  10  '~ trypan blue-excluding 
cells in 0.2 ml of HBSS intradermally in the flank. 
Detection of Membrane C3 Receptors.  Membrane receptors for the third component of the 
complement (C3) were identified on normal lymph node and L2C  cells, as previously described 
(15). Briefly, antigen-antibody-mouse complement complexes (EAC) were prepared by adding an 
equal volume of fresh mouse serum, diluted 1:10, to a  suspension of sheep blood cells precoated 
with rabbit 19S anti-Forssman antibody, a generous gift of Dr. M. Frank, Laboratory of Clinical 
Investigation, NIAID, NIH, Bethesda, Md. An aliquot (0.4 ml) of the lymphoid cell suspension (2 
x  i0  ~ cells/ml) to be tested was added to {).4 ml of  a suspension of EAC. The mixture was incubated 
at 37°C for 30 min with gentle agitation. The number oftrypan blue-excluding viable lymphocytes 
with three or more  erythrocytes attached to  the cell  surface  (rosettes) were enumerated in  a 
hemocytometer. 
Preparation of Alloantisera.  The immune sera used in  this study were prepared by  cross- 
immunization of animals of known phenotype with lymph node and spleen cells (approximately 
100 x  10'; cells per recipient) emulsified in complete Freund's adjuvant (CFA) containing 0.5 mg/ml 
of Mycobacterium butyricum  (Difco  Laboratories,  Detroit,  Mich.).  2  and  4  wk  after  primary 
immunization the animals were boosted by either subcutaneous or intraperitoneal injection of 100 
x  10" lymph node and spleen cells in HBSS. 6 wk after primary immunization the animals were 
exsanguinated, the sera heat inactivated at 56°C for 45 rain, and stored at  -70°C. St.  13  anti-2 
serum contains antibodies to two distinct GPLA specificities, Ia.2  and  Ia.4;  St.  2 anti-]3  also 
contains antibodies to two distinct GPLA specificities, Ia. 1 and Ia.3. Specific antisera to Ia.4 were 
raised by immunizing random-bred Ia.2 +, Ia.4- guinea pigs which possess the B.1 GPLA antigen 
with cells from inbred St. 2 (Ia.2,4, B.1) donors; antisera to Ia.2 were obtained by immunizing St. 
13 (Ia. 1,3, B. 1) animals with cells from Ia.2 + Ia.4-, B. 1  + random-bred animals. Antisera to the B. 1 
alloantigen was prepared as previously described (16). Further details concerning the nature of 
these antibodies will be presented in the result section. 
Immunofluorescence.  A direct immunofluorescence  technique was used to detect the presence 
of membrane immunoglobulins (Ig), as well as B and Ia alloantigens on the various L2C cell lines. 
Viable L2C and normal lymph node cells were incubated directly with fluorescinated antisera at 
4°C for 30 min. The cells were washed three times, suspended in HBSS, and examined under a 
petroleum jelly-lined cover slip with a Leitz-Ortholux microscope equipped with a vertical illumi- 
nator (E. Leitz, Rockleigh, N. J.). The presence of IgM idiotype determinants was determined by 
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incubated at 4°C for 15 min with a sheep antiserum to the idiotypic determinant(s) of membrane 
IgM of LE-L2C cells. This serum had been rendered specific by in vivo absorption in a normal St. 2 
animal  (17) and was kindly supplied by Dr.  G.  T.  Stevenson, Tenovous Research Laboratory, 
General  Hospital,  Southampton,  England.  The  cells were washed  three  times in  HBSS  and 
incubated with a fluorescein-conjugated  rabbit antisheep gamma globulin antiserum at 4°C for 30 
min. The cells were then washed three times and examined as described before. 
Cytotoxicity Testing.  The presence of individual alloantigens on L2C cell membranes was also 
tested by cytotoxicity. The :'~Cr-release assay was performed as previously described in detail (18). 
In brief, about 50 x  10" target cells were incubated in 1 ml of HBSS containing 10% fetal calf serum 
and 100 ~Ci of:'~Cr (sp act 200-500  ~Ci/~g, Amersham/Searle Corp., Des Plains, Ill.) for 60 min at 
37°C. The cells were then washed twice and resuspended at a concentration of 10 x  10  ~  cells/ml. 0.1 
ml of cell suspension was then added to 10  x  75 mm tubes, followed by 0.1 ml of 1:10 dilution of 
antiserum and 0.1 ml of 1:2 dilution of lyophilized guinea pig serum (Grand Island Biological Co., 
Grand Island, N.  Y.) as source of complement. The amount of radioactivity released was quanti- 
tated as follows: 
Radioactivity released by antiserum dilution 
:'Cr release (%)  =  100  x  -  radioactivity released in absence of antiserum 
Radioactivity released by frozen-thawed cells 
-  radioactivity released in absence of antiserum 
Absorption of  Alloantisera.  0.1 ml of the different guinea pig alloantisera were mixed with 0.9 
ml of an HBSS suspension containing 1 x  10  ~ normal or leukemic lymphocytes and incubated for 4 
h at 4°C on a rocking platform. The absorbed antisera were centrifuged at 30,000 rpm for 30 min. 
Immunization  and Subsequent Challenge.  St.  2 guinea pigs were immunized with leukemic 
cells as previously described (19). Briefly, leukemic cells in HBSS were emulsified with an equal 
volume of CFA.  An aliquot  (0.4  ml)  of the emulsion containing 20  x  10'; leukemic cells was 
distributed among the foot pads.  Control groups were injected with an emulsion of CFA-HBSS 
alone. The immunized and control animals were challenged 14 days after the immunization with 
10  x  10  '' viable L2C cells injected intradermally, except when otherwise specified. 
Assay of DNA Synthesis.  Cultures were performed in round bottom microtiter plates (Cooke 
Laboratory Products Div., Dynatech Laboratories Inc., Alexandria, Va.) in RPMI supplemented 
with L-glutamine (0.3 mg/ml), 200 IU/ml of penicillin, 100 gg/ml of streptemycin, and 10% guinea 
pig serum.  Responding lymph node cells were enriched in T  lymphocytes by purification over 
adherence columns as previously described (16), and were cultured in triplicate at a concentration 
of 2.4  x  10:' cells per well in a total vol of 0.2 ml. Stimulating cells were treated with 40 #g/ml of 
mitomycin C  (Sigma Chemical Co., St.  Louis, Mo.)  for 40 min at 37°C,  washed four times, and 
cultured at a concentration of 0.8 x  10:' cells per well. Microtiter plates were incubated at 37°C, in a 
humidified atmosphere of 5% CO2-95% air. 18 h before harvesting i  gCi of tritiated thymidine (sp 
act 6.7  Ci/mmol; New England Nuclear, Boston, Mass.) was added to each well. Cultures were 
collected with the aid of a  semiautomatic microharvesting device and the amount of tritiated 
thymidine incorporated was determined by liquid scintillation spectrometry and expressed as total 
counts per minute. 
Results 
Derivation of L2C Lines.  The L2C leukemia is an acute leukemia of guinea 
pigs which arose in an old unirradiated control St. 2 female sometime between 
1942 and  1953 during a  research study by Congdon and co-workers  (11, 12), 
whose primary goal was to analyze the biological effect of long-term whole body 
~/and X irradiation. This leukemia has been serially transplanted in inbred St. 2 
and in (St: 2  x  Hartley)F~ guinea pigs for over 20 yr. Initially, L2C leukemia 
was maintained at the  National Cancer Institute, then by C.  W.  Jungeblut 
(13),  and  on  collaborative  basis  by  E.  M.  Nadel  and  S.  Burstein  (14) who 
provided starter material of this leukemia line to several laboratories. The five 1070  Ia  ALLOANTIGENS  AND  TATA 
L2C lines analyzed in the present study were recently obtained from different 
laboratories in which L2C leukemia had been actively transplanted for various 
lengths of time. Since the L2C leukemia has been maintained and studied at 
various times for more than 20  yr by several investigators, it is  difficult to 
identify the  exact  sequence  of the  transmission  of the  leukemia  from  one 
investigator to another. However, it should be noted and will be discussed in 
detail in another paper, that all the five different lines bear two X chromosomes 
and an identical extra metacentric chromosome indicating a common ancestral 
origin." 
Course of L2C Leukemias in Untreated St. 2 Guinea Pigs.  The intradermal 
inoculation in St. 2 animals of 10 ×  106 leukemic cells, in 0.2 ml of HBSS of all 
the five leukemic lines tested consistently induced a generalized acute leukemia 
with  a  rather  characteristic clinic  course.  A  hemorrhagic nodular leukemic 
tumor appears at the intradermal injection site about 7 days after inoculation. 
Shortly after, when the intradermal tumor reaches about 10-15 mm in diameter, 
a progressive systemic disease is manifested by increasing leukocytosis, with a 
doubling time of about 24 h, abdominal distension with palpable hepatospleno- 
megaly, marked ataxia, and death with neurological manifestations about 12-24 
h after the leukemic cells have reached 200,000 cells/mm  3. Gross autopsy exami- 
nations revealed a spleen 6-10  times the normal size, considerable hepatomeg- 
aly, and enlarged lymph nodes. The pathological manifestations and cytomor- 
phology were similar in all five of the L2C lines studied, and were similar to the 
findings previously reported by Opler (20). 
Expression of C3 Receptors.  In previous studies, we have demonstrated that 
LE-L2C cells bear on the membrane multiple markers (C3 receptors and surface 
Ig) characteristics of bone marrow-derived (B) lymphocytes and therefore the 
L2C leukemia was interpreted as a leukemia of B-cell origin (15). Therefore we 
have comparatively analyzed the presence of some membrane markers on the 
various L2C  lines  (Table  I).  The presence  of complement  (C3) receptor  was 
determined by incubating the leukemic cells with EAC. As previously reported 
(15), EAC rosettes with three or more erythrocytes can be detected on 75-80% of 
LE-L2C cells. A substantial percentage (40-50%) of GH-L2C and EN-L2C cells 
also form EAC rosettes. Significantly fewer LG-L2C and BZ-L2C cells formed 
percentage of EAC rosettes. 
Presence  of Surface  Immunoglobulins  and  a  Common  Idiotypic  Determi- 
nant.  Surface  Ig  were  constantly detected by  a  direct immunofiuorescence 
technique on more than 90% of cells from each of the five L2C cell lines using a 
polyspecific rabbit antiguinea pig Ig antiserum. These data are shown in Table 
I. Moreover, with an antiguinea pig IgM antiserum, the surface Ig was identi- 
fied as IgM on both LE-L2C (17) and BZ-L2C leukemia cells (G. T. Stevenson, 
personal  communication). Recent studies of solubilized membrane-associated 
immunoglobulin indicate that the surface IgM ofLE-L2C, GH-L2C, and BZ-L2C 
cells is monomeric (F. Finkelman and B. Schwartz, unpublished observations). 
Whang-Peng, J., E. C. Lee, G. Forni, and I. Green. 1975. Mutant lines of guinea pig L2C 
leukemia. II. Comparative cytogenetic  studies and banding analysis of normal and leukemic 
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TABLE  I 
Surface Markers of the Five L2C Leukemic Lines 
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Presence of a 
Presence of C3 re-  Presence of  common idi- 
Surface IgM 
ceptors  surface Ig  otypic deter- 
minant 
% of fiuores-  % of fluores- 
cent cells with  Cells positive  cent cells with 
% of EAC rosette- 
forming cells  an antiguinea  with an anti-  an anti-LE- 
pig Ig antise-  IgM antiserums  L2C Ig idi- 
rum*  otype serum§ 
LE-L2C  75-80  >90  Yes  >90 
LG-L2C  40-50  >90  ND[I  >90 
EN-L2C  40-50  >90  ND  >90 
GH-L2C  10  >90  ND  >90 
BZ-L2C  >3  >90  Yes  >90 
* Determined by direct immunofluorescence  technique using an antiserum with broad specificity. 
$ G.  T.  Stevenson, personal communication and reference 17. 
§ Determined by indirect immunofluorescence using a highly specific anti-idiotypic antibody (see 
text). 
I[ ND, not done. 
The various L2C lines were then tested for a common IgM idiotypic determi- 
nant by indirect immunofluorescence using an anti-idiotype antiserum prepared 
against IgM extracted from LE-L2C cells (17). When the antiserum was tested 
against cells of  the five L2C lines, each displayed an identical pattern of  uniform 
circumferential staining with superimposed bright spots on more than 30% of 
the cells (Table I). In contrast, no staining of normal St. 2 or St. 13 lymph node 
cells, known to contain about 35% B lymphocytes, was observed. These results 
indicate the presence of a  common idiotypic determinant on all the L2C lines 
studied and the absence of appreciable numbers of idiotype-bearing cells from 
normal lymphoid populations.  However,  in  spite  of the  binding detected by 
immunofluorescence, the anti-idiotype antiserum was not cytotoxic for any of 
the L2C lines in presence of complement, when tested by a  :'lCr-release tech- 
nique. 
Expression of Alloantigens of the GPLA.  Although the serological analysis 
of GPLA is  not  completely determined,  recent  serological,  genetic  (21), and 
physiochemical (22) studies have identified two linked regions or loci. The B 
region codes for at least four allelic specificities termed B.1, B.2, B .3, and B.4 
which appear to be the guinea pig equivalent of the murine D- or K-region gene 
products. Inbred St. 2 and St.  13 animals both bear the B.1  allele and the sera 
raised by cross-immunization of these two inbred strains identify what appears 
to be the guinea pig equivalent of the murine Ia antigens. St. 2 anti-13 serum 
contains antibodies to two specificities termed Ia. 1 and Ia.3, while St. 13 anti-2 
serum contain antibodies to two distinct specificities Ia.2 and Ia.4. It has been 
demonstrated that the alloantigens coded by these two regions differ in their 
tissue distribution. The Ia alloantigens are restricted to lymphoid cells while the 
B alloantigens have a wide tissue distribution. 1072  Ia  ALLOANTIGENS  AND  TATA 
TABLE II 
Presence of I- and B-Region Antigens on Normal Lymphocytes and L2C Cells 
Target Cells 
Percentage of :'~Cr released by different antisera* 
St.  13  St. 2 anti- 
Anti-Ia.2  Anti-Ia.4  Anti-B. 1 
anti-2$  13§ 
Normal St. 2 lymph node cells  59  30  28  0  85 
Normal St.  13 lymph node cells  0  0  0  30  80 
LE-L2C  75  NDII  ND  0  88 
GH-L2C  70  20  77  0  30 
EN-L2C  73  85  80  0  88 
LG-L2C  75  22  70  0  85 
BZ-L2C  1  0  0  0  85 
BZ-L2C  after  treatment  with  3  ND  ND  1  90 
neuraminidase 
* Final dilution 1:30. 
St.  13 anti-2 sera contain antibodies to both Ia,2 and Ia.4 alloantigens. 
§ St. 2 anti-13 sera contain antibodies to both Ia.1 and Ia.3 alloantigens. 
II ND, not done. 
We next studied the different leukemic lines for the presence of B-  and I- 
region gene products both by indirect immunofluorescence and by a  comple- 
ment-dependent •  ~Cr-release cytotoxicity assay (Table  II).  St.  13  anti-2 sera, 
which contain antibodies directed to Ia.2 and Ia.4 specificities stain LE-L2C, 
GH-L2C,  EN-L2C,  and  LG-L2C cells.  Moreover,  these  Ia  antigens could  be 
capped independently of membrane immunoglobulins (I.  Green,  unpublished 
observations). In contrast no Ia.2-Ia.4-specific staining was detectable on BZ- 
L2C cells.  Similarly, the ='~Cr-release technique performed with either St.  13 
anti-2 antisera or with monospecific anti-Ia.2 and anti-Ia.4 antisera detected 
these  two  alloantigens on  all  L2C  lines  except the  BZ-L2C  line.  Moreover, 
absorption of St. 13 anti-2 antisera with a large excess of BZ-L2C cells failed to 
remove the cytotoxic antibodies directed against St. 2 Ia specificities. However, 
it should also be noted that differences were repeatedly observed in the percent- 
age of :"Cr released from the various Ia-positive L2C lines with the monospecific 
anti-Ia.2 sera suggesting that these lines differed in the amount of Ia.2 antigen 
they contained.  Finally to  exclude the  possibility that Ia.2,  Ia.4 specificities 
were expressed on the BZ-L2C cell membrane, but were masked by sialic acid 
residues,  often produced in higher amount in transformed cells,  the  BZ-L2C 
cells were treated with 100 ~g of neuraminidase for 30 min at 37°C. Even after 
this treatment no Ia specificities were detectable on BZ-L2C cell membranes. As 
anticipated, no Ia.l,3 specificities were detectable on any of the L2C leukemic 
lines. 
Alloantisera  monospecific for  B.1  alloantigens  stained  all  the  L2C  lines 
equally well.  In addition, anti-B.1  antisera,  in the presence  of complement, 
lysed cells  from  each  of the  five  L2C  leukemic  lines.  The  amount of lysis 
obtained with the L2C cells was comparable to the degree of lysis observed with 
normal St.  2 and St.  13 spleen cells both of which express the B.1  specificity 
(Table II). Moreover studies of ~2'I-surface  labeled and of :~H-leucine internally GUIDO  FORNI,  ETHAN  M.  8HEVACH,  AND  IRA  GREEN 
TABLE  III 
Growth and Rejection of GH-L2C and BZ-L2C in Guinea Pigs of Different 
Histocompatibility  Type 
Identified histocompatibility an- 
Leukemic line injected  Recipient animal*  tigens 
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B  I 
Takes$ 
GH-L2C (B.1, Ia.2, Ia.4)  St. 2  B.1  Ia.2, Ia.4  40/40 
St. 13  B.1  Ia.1, Ia.3  0/20 
Random bred  B. 1  Ia.2,4§  0/8 
Random bred  B. 1  Ia. 1,3§  0/6 
Random bred  B.1  Ia.l,3; Ia.2,4§  0/3 
Random bred  B.1; B.3  Ia.1,3*;  Ia.2,4§  0/3 
Random bred  B.3  Ia. 1,3"  0/4 
BZ-L2C (B.I,  Ia absent)  St. 2  B.1  Ia.2; Ia.4  20/20 
St. 13  B.1  Ia.1, Ia.2  20/20 
Random bred  B. 1  Ia.2,4§  5/5 
Random bred  B.1  Ia.l,3§  8/8 
Random bred  B.I  la.l,3§;  Ia.2,4§  3/3 
Random bred  B.1;  B.3  la.l,3§;  Ia.2,4§  2/2 
Random bred  B.3  Ia.2,4§  0/4 
Random bred  B.3  la.1,3§  0/3 
* Challenged with I0 x I0" leukemic cells. 
Leukemic animals 45 days after  challenge. 
§ In  these  animals  Ia  specificities  have  been  identified  by  antisera  directed  to  both  la.2  and  la.4,  or 
to  both la.  1  and la.3  alloantigens  and  therefore  an animal  that  lacked one  of  two  Ia  specificities 
could not be detected. 
labeled GPLA antigens indicated no differences in the molecular characteristics 
of B.1 and Ia.2,4 alloantigens on LE-L2C, GH-L2C, and normal St. 2 lymphoid 
cells, at least when studied by sodium dodecyl sulfate-polyacrylamide gel elec- 
trophoresis.  By contrast a  normal B.1 alloantigen but no Ia alloantigens were 
detected on BZ-L2C cells by these techniques (F. Finkelman and B. Schwartz, 
unpublished observations). 
Transplantation  of GH-L2C  and BZ-L2C Leukemias  into  Guinea  Pigs of 
Different Histocompatibility  Type.  The antigens  of the GPLA have been de- 
fined mainly by serological and genetic studies. The transplantation data avail- 
able were obtained by skin  grafting  (23),  by transfer of nonlymphoid tumors 
which do not bear Ia alloantigens on the membrane (24), and by limited studies 
with LE-L2C leukemia cells (25). It was therefore of great interest to study the 
growth and rejection patterns of these leukemic lines in recipient animals that 
differed at  either the I  or B  loci  and  to attempt  to correlate the presence  of 
absence  of Ia  antigens  on the  leukemic cells with differences in  growth  and 
rejection patterns. For these studies we have used GH-L2C cells as Ia-positive, 
and BZ-L2C as Ia-negative leukemic cell lines. The results of these studies are 
shown in Table III. 
The inoculation  of 10  x  10  ~ GH-L2C cells into random-bred animals  which 
differ at either,  or both,  the I  or B  loci, resulted in the formation of a  small 1074  Ia  ALLOANTIGENS  AND  TATA 
erythematous papule 24-48 h  after the challenge followed, in every case, by a 
complete rejection of the leukemia cells with the formation of a small cutaneous 
scar.  Surprisingly,  when  injected  in random-bred  guinea  pigs from the  NIH 
colony, which initially were thought to possess the B. 1, Ia.2, and Ia.4 alloanti- 
gens, the GH-L2C leukemia cells were also rejected. This rejection was at first 
thought to be due to the presence of an as yet unidentified alloantigen.  However, 
recent studies of the alloantigens  of the animals  of the NIH colony done with 
monospecific anti-Ia.2 and Ia.4 antisera (not available before) indicated that the 
great majority of random-bred animals of the NIH colony which were thought to 
be both Ia.2  and  Ia.4 positive are actually Ia.2 positive and Ia.4  negative.  In 
retrospect, these data suggest that the rejection of GH-L2C leukemia in animals 
thought to have been B.1, Ia.2, and Ia.4 positive was actually dependent on the 
absence of Ia.4 alloantigen in the recipient animal. 
A  quite  different  growth-rejection  pattern  was  observed upon  challenge  of 
allogeneic animals with the BZ-L2C leukemia, which does not express Ia anti- 
gens  on  the  membrane.  These  leukemic  cells could  be transplanted  into  all 
random-bred animals that were B. 1 positive without regard to which Ia antigens 
the recipient possessed. However, the BZ-L2C leukemia was uniformly rejected 
in B.l-negative animals  (Table III). This growth-rejection pattern confirms the 
dominant role played by the B  alloantigens  in rejection of tumors that do not 
bear Ia antigens on their surface (24).  Thus, the results with the GH-L2C and 
BZ-L2C leukemias indicate that antigens on the cell surface coded for by genes 
at both the/andB  loci can act as transplantation antigens in the guinea pig. 
Presence of TA TA.  The presence of TATA on L2C cells was determined in 
the present study by the results of immunization protection tests. Immunization 
was achieved by injecting the leukemic cells emulsified in  CFA into the  foot 
pads of St.  2 guinea pigs.  Irradiated  cells and unirradiated  cells were equally 
effective.  As  can  be  seen in  Table  IV,  St.  2 guinea  pigs immunized  14  days 
earlier with LE-L2C,  GH-L2C, EN-L2C,  and LG-L2C cells emulsified in CFA, 
were almost completely protected against  a  subsequent challenge  with viable 
cells of the line which has been used for immunization.  Moreover, 24-48 h after 
the intradermal  challenge  a  skin reaction  with induration  and erythema was 
evident.  By contrast,  guinea pigs which had been immunized  and challenged 
with the Ia-negative BZ-L2C leukemia cells displayed no protection or increased 
survival as compared to unimmunized controls, confirming what previously has 
been reported for this particular leukemic line by Wepsic et al.  (26).  In a criss- 
cross  immunization-protection  experiment  we then  examined  whether  cross- 
protection between the different leukemic lines could be obtained. St. 2 animals 
which had been immunized with GH-L2C, EN-L2C, or LG°L2C were completely 
protected against a challenge with any of these leukemic lines, indicating that 
these three lines share a common TATA (Table V). St. 2 guinea pigs preimmu- 
nized  with  BZ-L2C  displayed no  significant  protection  or  prolonged  survival 
upon challenge  with  any of the other leukemia lines compared to the control 
animal groups injected with HBSS-CFA. Surprisingly, however, animals preim- 
munized with GH-L2C, EN-L2C, or LG-L2C were completely protected against 
challenge with the apparently nonantigenic BZ-L2C leukemia cells. Thus, these 
crisscross protection tests indicate the presence of a  common TATA in each of GUIDO  FORNI,  ETHAN  M.  SHEVACH,  AND  IRA  GREEN 
TABLE  IV 
Immunogenicity of Different L2C Lines in Syngeneic St. 2 Guinea Pigs 
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Immunization  Challenge* 
Surviving animals 
45 days after chal- 
lenge 
20 ×  10"  LE-L2C cells  in CFA  LE-L2C cells  14/15 
HBSS  in CFA  LE-L2C cells  1/16 
20 ×  10  ~ GH-L2C  cells  in CFA  GH-L2C  cells  14/14 
HBSS  in CFA  GH-L2C  cells  0/12 
20 x 10  ~ EN-L2C  cells  in CFA  EN-L2C  cells  5/5 
HBSS  in CFA  EN-L2C  cells  0/5 
20 ×  10" LG-L2C cells  in CFA  LG-L2C cells  5/5 
HBSS in CFA  LG-L2C cells  0/4 
20  x  10"  BZ-L2C  cells in CFA  BZ-L2C  cells  0/9 
HBSS in CFA  BZ-L2C  cells  0/10 
* Challenge was performed 14 days after the immunization with 10  x  10  '~ cells injected intrader- 
mally. 
the  L2C  lines.  However the  BZ-L2C  appears  to  possess  a  "TATA" which is 
incapable of eliciting an immune response. 
Stimulation  of St.  2  Lymphocytes  Proliferation  By  L2C  Cells.  We  next 
analyzed the capacity of cells of the various L2C lines to stimulate proliferation 
of  lymphocytes obtained from control or from preimmunized St. 2 guinea pigs. 
Lymphocytes from  control  donors  did  not  develop  a  detectable  response 
against leukemic cells.  By contrast,  an anamnestic lymphocyte proliferative 
response  was  initiated  in  lymphocytes from  St.  2  animals  which  had  been 
preimmunized 14 days before with Ia-positive L2C leukemia cells by each of the 
various L2C lines tested, including the Ia-negative BZ-L2C line (Table VI).  No 
significant differences were observed in the DNA-synthetic response of preim- 
munized St. 2 lymphocytes stimulated by the various L2C cell lines. Moreover, 
these data obtained with these four L2C cell lines tested were consistent with 
the data we have previously obtained with LE-L2C-stimulating cells (19). In 
contrast no  anamnestic proliferative response  against any L2C  cell line was 
observed  with  lymphoid cells  obtained  from  St.  2  animals  which had  been 
preimmunized with the Ia-negative BZ-L2C cells. 
Discussion 
The data obtained in the present study demonstrate that there are several 
different lines of L2C leukemia and that an important correlation can be made 
between the surface antigenic structure of these cells and their immunogenic 
potential. The presence of an identical chromosomal marker and the presence of 
the  same  idiotypic determinant on the  surface  Ig of the  five different lines 
analyzed, overwhelmingly indicate that  these  lines  are  mutants of a  single 
parental  line.  A  detailed  analysis  of the  karyotypes of each  of these  five 
leukemic  lines,  which  will  be  reported  elsewhere  (see  footnote 2)  indicate, 
however, that each line presents a slightly different chromosomal pattern and 
therefore each line is a distinct mutant arising during the passage of the L2C 
leukemia in various laboratories. 1076  Ia  ALLOANTIGENS  AND  TATA 
TABLE  V 
Cross-Protection against the Various L2C Lines Induced by 
Preimmunization of Syngeneic Strain 2  Guinea Pigs with Different 
L2C Cells 
L2C cell line used for im-  L2C cell line used for  Surviving animals 







GH-L2C  0/7 
EN-L2C  0/6 
LG-L2C  0/9 
BZ-L2C  0/8 
EN-L2C  6/6 
LG-L2C  5/5 
BZ-L2C  7/7 
GH-L2C  6/6 
LG-L2C  4/4 
BZ-L2C  4/4 
GH-L2C  5/5 
EN-L2C  5/5 
BZ-L2C  5/5 
GH-L2C  1/7 
EN-L2C  0/4 
LG-L2C  0/5 
* Immunization  with 20  x  10  ~ cells emulsified in CFA. 
Challenge  with 10  x  10" living cells.  Challenge performed 14 days after the 
immunization. 
§ Injected with HBSS-CFA  only. 
These lymphoid tumors of B-cell origin, most of which express both the GPLA 
B  and Ia antigens,  permitted us to undertake a more complete analysis of the 
role of the different GPLA specificities in tissue transplantation than had been 
previously possible.  The GH-L2C leukemic line which bore both the B  and Ia 
alloantigens would only grow in syngeneic St.  2 animals and failed to grow in 
B.1 compatible but Ia distinct St.  13 guinea pigs or in random-bred animals of 
various  histocompatibility  types.  In  contrast,  the  BZ-L2C  line,  which was  Ia 
negative, grew readily in both St. 2 and St.  13 animals. Moreover the ability of 
this line to grow in random-bred guinea pigs was only related to the presence or 
absence of B. 1 antigen in the recipient. The growth-rejection pattern of this Ia- 
negative leukemic line is therefore identical to the pattern previously observed 
with nonlymphoid, Ia-negative tumors (24). In the case of the Ia-positive variant 
(GH-L2C) the Ia antigen (and probably the B antigen) appears to function as a 
transplantation antigen,  while in the case of the Ia-negative variant  (BZ-L2C) 
the B. 1 antigen functions as a transplantation antigen. Recent studies have also 
demonstrated  that  cell  surface  antigens  coded by  the I  region  of the  murine 
MHC can act as transplantation antigens  (27,  28). 
Of particular  interest  is  the  data  on  the  immunogenicity  of the  different GUIDO  FORNI,  ETHAN  M.  SHEVACH,  AND  IRA  GREEN  1077 
TABLE  VI 
DNA-Synthetic Response to L2C Leukemic Cells of  Lymph Node Cells from St. 2 Guinea 
Pigs Preimmunized with GH-L2C or BZ-L2C 
Effector lym- 
phocytes from  Stimulator 
strain 2 ani-  cells  mals preim- 
munized with: 
St. 2 Lymph node cells |ZH]thymidine incorporation* 
72 h  120 h  144 h 
GH-L2C  -  489  ±  85  534  ±  37  565  ±  100 
GH-L2C  2,327  ±  150  13,614  +-  559  7,858  ±  1,336 
EN-L2C  4,767  ± 600  15,857  +- 432  9,274 ± 1,176 
LG-L2C  4,777 _+ 760  11,802  ± 559  5,107  ± 1,230 
BZ-L2C  3,132 _+ 169  12,075  ± 470  9,220 ± 637 
BZ-L2C  -  403  ±  15  945  ±  138  709  ±  89 
GH-L2C  371  ±  32  975  ±  91  1,000  _+  105 
EN-L2C  290 ± 91  924 ± 89  768 ± 63 
LG-L2C  389 ± 35  763 ± 53  952 ± 110 
BZ-L2C  367 ± 88  853 ± 65  721 ± 98 
* Results are expressed  as mean counts per minutes ± SE of triplicate determinations. 
leukemic lines. The present study demonstrates that the four Ia-positive leuke- 
mia lines bear a  TATA which  is able to induce  specific resistance  to a  subse- 
quent  challenge  with  the  leukemia  cells  of the  same  line  in  St.  2  hosts.  In 
contrast,  the  Ia-negative  mutant  line  (BZ-L2C)  did  not  possess  TATAs  as 
measured by the same type of immunization and challenge experiments (Table 
V) demonstrated that it is not simply that BZ-L2C leukemia cells lack a  TATA 
but rather the TATA of this particular mutant is not immunogenic. That is, St. 
2 animals preimmunized with cells of any of the Ia-positive L2C leukemic lines 
can  subsequently  reject  a  challenge  with  the  BZ-L2C  leukemia  cells.  These 
results indicate  that  BZ-L2C cells share  a  common TATA with the other L2C 
leukemias, and that it can be recognized by immunized recipients, but that this 
TATA is not immunogenic when it is present on the BZ-L2C cell. Moreover, an 
in vitro anamnestic proliferative response of lymph node cells from St. 2 guinea 
pigs against the Ia-positive and Ia-negative leukemic lines can be obtained only 
with lymphocytes from animals preimmunized with the Ia-positive but not the 
Ia-negative L2C lines (Table VI). These in vivo and in vitro experiments point to 
a relationship between the immunogenicity of L2C cells and the expression of Ia 
alloantigens.  In both,  the  in vivo and in vitro experiments,  the immunization 
with the Ia-negative BZ-L2C cells failed to elicit a  population of TATA-respon- 
sive T lymphocytes suggesting that the presence of Ia alloantigens is a necessary 
requirement for the elicitation of a primary immune response to the L2C TATA. 
Although the role of the Ia antigens  in the immune response in general has 
been  incompletely  defined,  the  Ia  antigens  or  the  products  of closely  linked 
genes appear to play a  central role in the interaction of immunocompetent cells. 
Thus,  a  requirement  for  shared  Ia  antigens  has  been  demonstrated  for  the 
interaction  of macrophages  and  lymphocytes  required  for  the  generation  of 
helper T-cell activity in mice (29), for the passive transfer of delayed hypersensi- 
tivity in mice (6), and for antigen-induced T-cell proliferation in guinea pigs (4, 1078  Ia  ALLOANTIGENS  AND  TATA 
5).  Although  it  is  well  accepted  that  macrophages  play  a  major  role  in  the 
processing of soluble protein antigens,  the role of the macrophage in the induc- 
tion of the immune response to membrane alloantigens  and tumor-antigens  is 
less  well  established.  Nevertheless,  the  lack  of immunogenicity  of the  Ia- 
negative  leukemic  cells  (despite  the  fact  it  bears  a  common  TATA)  can  be 
explained  in  the  context  of what  is  known  about  the  requirements  for  the 
response  to  more  defined antigens.  One  possible mechanism  for  a  successful 
immunological event is a direct interaction between the Ia antigens of lymphoid 
tumors and  the host T  cells.  Thus,  in the present study it is possible that  Ia 
alloantigens are necessary structures to allow a physical contact between lym- 
phocytes and leukemic cells bearing TATAs, which is required for an effective 
immune response to the TATA to be generated.  A second possibility is that the 
TATA must be processed in vivo by host macrophages and that Ia antigens of 
the tumor cells act as an integral part of the TATA molecular organization and 
are required for immunogenicity.  According to this  hypothesis it would seem 
that Ia antigens  of host macrophages  (in which the tumor antigens are "proc- 
essed") cannot substitute for the Ia antigens which are an integral  part of the 
tumor cell membrane.  Thus, the Ia antigens may be functionally equivalent to 
the carrier portion of the tumor-specific determinants,  analogous to the protein 
portion of the immunogen in the case of hapten-protein  conjugates.  A  similar 
carrier role of normal membrane antigens for TATAs has been recently reported 
on a murine adenocarcinoma (30). However the hapten-carrier analogy is imper- 
fect  in  that  the  hapten-positive  carrier-negative  BZ-L2C  cells  were  able  to 
stimulate in a mixed leukocyte tumor interaction and presumably were lysed by 
specific cytotoxic T cells in vivo. In these situations perhaps the product of the 
guinea pig B region acted as carrier  molecule (see below). 
An  analogy  can  be drawn  between our findings  obtained  in  vivo and  the 
studies of the  generation  of cytotoxic effector cells in  mouse mixed leukocyte 
culture in vitro. Here two conditions appear to be necessary; Ia differences must 
be present to generate a  mixed leukocyte reaction and at the same time H2-K 
and/or H-2D differences are required on the cells undergoing the mixed lympho- 
cyte reaction  for the  generation  of killer  cells.  Finally  the  target  cells  must 
contain the relevant H2-K and/or H2-D alloantigen.  In this in vitro system an 
effective cytotoxic activity does not develop in the absence of Ia differences (31, 
32). 
The data presented here are also consistent with recent observations which 
suggest that  the  most highly  immunogenic  TATAs  may represent  altered  or 
modified H-2 antigens  (10, 33-36). Thus, Germain et al.  (10) demonstrated that 
alloantisera  raised  by immunization  with  normal  lymphoid cells  can  inhibit 
lysis  of tumor  targets  by  syngeneic  immune  T  lymphocytes.  An  intriguing 
possibility,  suggested by our in  vivo and  in  vitro  results,  is  that  the  TATA 
associated with the products of the I  region may be important for the induction 
of the immune response, while the same TATA associated with the products of 
the B  region which is the guinea pig equivalent of the mouse D- and K-region 
products is important as the target for specific cytotoxic T lymphocytes. It would 
be of interest to evaluate the effect of anti-B. 1 serum in an in vitro assay of T-cell 
cytotoxicity against  L2C.  However, we have been hampered  in these studies GUIDO  FORNI,  ETHAN  M.  SHEVACH,  AND  IRA  GREEN  1079 
because  of the  present  lack  of a  suitable assay of T-cell  cytotoxicity in  this 
particular system. Although the present data suggest that the deletion of Ia 
alloantigens is associated with a loss in immunogenicity of TATA, it is possible 
that such an association is merely coincidental. Studies are now in progress with 
solubilized membrane antigens to determine the requirement of Ia alloantigens 
in the immunological recognition of L2C TATA in syngeneic guinea pigs. 
Studies of the relationship between Ia antigens and antigenicity of TATA in 
this series of guinea pig B-cell malignancies may provide a model for studies of 
this relationship in human leukemic cells and may be especially relevant since 
it  has  been  recently  demonstrated  that  a  high  proportion  of acute  human 
lymphocytic leukemias resemble B cells in carrying Ia-like antigens (37). 
Summary 
Five different lines of a strain 2 guinea pig leukemia (L2C) which had been 
carried in different laboratories share certain chromosomal markers and have a 
common surface  immunoglobulin idiotypic determinant indicating that they 
have a common origin. All these leukemic lines have on their surface of the B 
alloantigen (equivalent of the murine H-2K and H-2D  antigens)  and four of 
these five lines have on their surface the Ia alloantigens normally present on the 
strain 2 lymphocytes. The result of a study of the growth and rejection patterns 
of these leukemias in inbred and random-bred guinea pigs of selected histocom- 
patibility type indicates that both the B and Ia antigens can act as transplanta- 
tion antigens in guinea pigs. Immunization protection tests in syngeneic ani- 
mals  demonstrated  that  the  four  Ia-positive  leukemias  possessed  a  tumor- 
associated transplantation antigen(TATA), while the one Ia-negative leukemia 
by this criteria did not appear to have TATA. However, crisscross immunization 
protection tests demonstrated that preimmunization of syngeneic animals with 
an Ia-positive L2C line lead to a subsequent protection against challenge with 
the Ia-negative leukemia. Immunization with the Ia-negative line never pro- 
tected against a  subsequent challenge with any of the leukemic cells of L2C 
lines. These results strongly suggest that the Ia-negative leukemia possessed a 
TATA that can be recognized but is not itself immunogenic, and also indicate 
that Ia antigens on L2C cells are functionally associated with TATA and can act 
as immunological carriers for tumor transplantation determinants. 
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